Under the agreement, Merck will dedicate two of its U.S. facilities to producing Johnson & Johnson’s vaccine. One will produce doses, and the other will be for filling the vials with the vaccine and packaging them before distribution.
Merck discontinued the development of its two COVID-19 vaccine candidates Jan. 25.
More articles on pharmacy:
How J&J’s COVID-19 vaccine compares to Moderna’s, Pfizer’s
Pharmacy operator to pay Roche $43M to settle fraudulent rebates lawsuit
Florida expands eligibility for COVID-19 vaccines at retail pharmacies, physician offices
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
